Last time we mentioned General Motors Co (NYSE:GM), the stock was fresh off a post-earnings four-year peak.

I rate GE Vernova a "Buy," driven by rapid earnings growth and its pivotal role in AI-driven power infrastructure. Q3 results showed 10% organic revenue growth, robust margin expansion, and a $135 billion backlog, with the Electrification segment growth prospects exceeding 25%. Investor Day guidance lifted 2028 revenue targets to $52 billion and EBITDA margin to 20%, with a doubled dividend and $1 billion capex for Electrification.

Three consumer goods stocks recently announced significant share repurchase authorizations, and all three now have buyback capacity equal to 5% or more of their market capitalization.

New York, New York--(Newsfile Corp. - December 29, 2025) - Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against CarMax, Inc. (NYSE: KMX) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in CarMax, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/carmax-inc-class-action-lawsuit.

New York, New York--(Newsfile Corp. - December 29, 2025) - Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. (NYSE: ARE) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Alexandria Real Estate, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/alexandria-real-estate-class-action-lawsuit.

New York, New York--(Newsfile Corp. - December 29, 2025) - Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/inspire-medical-systems-inc-class-action-lawsuit.

New York, New York--(Newsfile Corp. - December 29, 2025) - Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Stride, Inc. (NYSE: LRN) and certain of the Company's senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws. If you invested in Stride, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/stride-inc-class-action-lawsuit.

New York, New York--(Newsfile Corp. - December 29, 2025) - Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Synopsys, Inc. (NASDAQ: SNPS) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Synopsys, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit.

New York, New York--(Newsfile Corp. - December 29, 2025) - Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Integer, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/integer-holdings-corporation-class-action-lawsuit.

NEW YORK, NY / ACCESS Newswire / December 29, 2025 / Most companies define market opportunity by demand signals. In regulated environments, the real driver is enforcement.

If you're invested in the broad market, you almost certainly have exposure to the megacap tech firms that have defined the S&P 500 for over a year. While the megacap tech names have delivered strong performances for portfolios, they continue to represent some notable concentration risk.

Intel Corporation (NASDAQ: INTC) had a 2024 to forget. The chipmaker lost more than 50% of its market value, and its stock was kicked out of the Dow Jones Industrial Average after 25 years.

Nu outperformed the S&P 500 over the past 12 months. It's still gaining customers without sacrificing its margins.

Ultragenyx Pharmaceuticals reported Phase 3 results for setrusumab, a potential treatment for osteogenesis imperfecta. Several firms have reduced their price targets on Ultragenyx stock.

Memberships remain Costco's core profit engine. Steady sales growth matters more than flashy growth.

The chipmaker's AI-inference agreement with startup Groq indicates growing competition for top talent and technology.

PEP aims to boost margins through cost cuts, automation and global productivity, despite ongoing pressures and uneven segment performance.

NEW YORK CITY, NEW YORK / ACCESS Newswire / December 29, 2025 / Most companies still think of verification as a feature. A box to check.

Edgewise Therapeutics, Inc. maintains a Buy rating, driven by favorable interim 12-week safety data for EDG-7500 in phase 2 CIRRUS-HCM and multiple 2026 catalysts. EDG-7500 demonstrated strong tolerability and no clinically meaningful LVEF reductions, potentially differentiating it from cardiac myosin inhibitors for HCM treatment. Key 2026 catalysts include phase 2 CIRRUS-HCM efficacy data in Q2 2026 and potential phase 3 initiation for EDG-7500 in Q4 2026, targeting both oHCM and nHCM patients.

With CHRW shares moving north, we assess the current positioning of the stock to determine if it's a good investment at this juncture.